Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Wednesday, February 24, 2021
8:00 AM – 9:00 AM (ET)
Grand Rounds Presentation

Faculty Presenter
Courtney DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Program Overview
Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

- Correlate disease pathophysiology, cytogenetic and molecular characteristics with targeted agents to individualize treatment of patients with AML
- Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
- Describe case scenarios in which maintenance therapy may become standard in the near future
- Assess the utility of MRD in selecting patients who will benefit most from maintenance therapy

Format
This program will provide a 1-hour slide presentation on exploring novel frontline treatments and prospects for maintenance therapy in AML including a case-based discussion and a question-and-answer session.

Accreditation
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.